Ainnocence PeptideAI Platform screens 3.2M peptides with 90%+ accuracy in activity and therapeutic property predictions
Foundation model-powered dual-module system establishes a new performance benchmark for AI-driven peptide drug discovery SAN FRANCISCO , CA, UNITED STATES, April 15, 2026 /EINPresswire.com/ -- Ainnocence, Inc. a next-generation AI drug discovery company …